Zeng Bin, Li Ying, Xia Jiang, Xiao Yin, Khan Nawaz, Jiang Bin, Liang Yujie, Duan Li
Graduate School Guangxi University of Chinese Medicine Nanning Guangxi China.
Department of Orthopedics, Shenzhen Intelligent Orthopaedics and Biomedical Innovation Platform, Guangdong Artificial Intelligence Biomedical Innovation Platform, Shenzhen Second People's Hospital the First Affiliated Hospital of Shenzhen University Shenzhen Guangdong China.
Bioeng Transl Med. 2024 Jan 11;9(2):e10623. doi: 10.1002/btm2.10623. eCollection 2024 Mar.
The biological barriers of the body, such as the blood-brain, placental, intestinal, skin, and air-blood, protect against invading viruses and bacteria while providing necessary physical support. However, these barriers also hinder the delivery of drugs to target tissues, reducing their therapeutic efficacy. Extracellular vesicles (EVs), nanostructures with a diameter ranging from 30 nm to 10 μm secreted by cells, offer a potential solution to this challenge. These natural vesicles can effectively pass through various biological barriers, facilitating intercellular communication. As a result, artificially engineered EVs that mimic or are superior to the natural ones have emerged as a promising drug delivery vehicle, capable of delivering drugs to almost any body part to treat various diseases. This review first provides an overview of the formation and cross-species uptake of natural EVs from different organisms, including animals, plants, and bacteria. Later, it explores the current clinical applications, perspectives, and challenges associated with using engineered EVs as a drug delivery platform. Finally, it aims to inspire further research to help bioengineered EVs effectively cross biological barriers to treat diseases.
人体的生物屏障,如血脑屏障、胎盘屏障、肠道屏障、皮肤屏障和气血屏障,在提供必要物理支撑的同时,能抵御入侵的病毒和细菌。然而,这些屏障也会阻碍药物向靶组织的递送,降低其治疗效果。细胞分泌的细胞外囊泡(EVs)是直径在30纳米至10微米之间的纳米结构,为这一挑战提供了潜在的解决方案。这些天然囊泡能够有效穿过各种生物屏障,促进细胞间通讯。因此,模仿天然囊泡或比天然囊泡更具优势的人工工程化EVs已成为一种很有前景的药物递送载体,能够将药物递送至几乎身体的任何部位以治疗各种疾病。本综述首先概述了来自不同生物体(包括动物、植物和细菌)的天然EVs的形成及跨物种摄取情况。随后,探讨了将工程化EVs用作药物递送平台的当前临床应用、前景及挑战。最后,旨在激发进一步的研究,以帮助生物工程化EVs有效穿过生物屏障来治疗疾病。